Boundless Bio is discovering and developing novel cancer therapeutics based on the role of extrachromosomal DNA (ecDNA) in driving tumorigenesis, resistance and recurrence.
When DNA in cancer cells comes off chromosomes, “extrachromosomal DNA (ecDNA),” it becomes unbound and unwound, thereby enabling numerous copies of cancer-causing genes, driving cancer cells to grow and allowing them to resist treatment. At Boundless Bio, we are counterattacking this ecDNA phenomenon with boundless innovation and boundless energy to develop powerful new cancer medicines that eliminate cancer cells’ ability to employ ecDNA to survive.
Our Culture:
At Boundless, you’ll experience what it means to be out in front of the wave.
Our unprecedented science takes us to new shores, and our team navigates the best breaks. We’re leaders in our field, and we’re dedicated to the cause of understanding and treating intractable cancers.
Every employee at Boundless makes an unbridled impact on our capabilities and our culture. We’ll help you expand your abilities and defy your bounds by providing meaningful work and unbounded opportunities. Career development is essential at Boundless.
We’re all in on this fight against cancer– collaboration is requisite to our success. We have a team of people who ask, offer, and accept help without regard for ego. We know that receiving support is energizing, and giving help is fulfilling. We are inspired by the patients who are reliant upon our success.
At Boundless, we’re all in. We are unbound by convention, bound to save lives.
Career Inquiries
careers@boundlessbio.com
General Information Inquiries
info@boundlessbio.com
Location: United States, California, La Jolla
Employees: 51-200
Total raised: $251.4M
Founded date: 2018
Investors 4
Date | Name | Website |
17.08.2021 | Logos Capi... | logoscapit... |
- | PFM Health... | pfmhealths... |
17.07.2021 | ARCH Ventu... | archventur... |
- | RA Capital... | racap.com |
Funding Rounds 3
Date | Series | Amount | Investors |
16.05.2023 | Series C | $100M | Logos Capi... |
24.05.2021 | Series B | $105M | - |
19.09.2019 | Series A | $46.4M | - |
Mentions in press and media 16
Date | Title | Description | Source |
28.03.2024 | Boundless Bio raises $100M from IPO | - | connect.or... |
16.05.2023 | Boundless Bio completes a $100M funding round to support the... | - | connect.or... |
16.05.2023 | Boundless Bio Raises $100M in Series C Financing | Boundless Bio, a San Diego, CA-based clinical stage precision oncology company, raised $100M in Seri... | finsmes.co... |
24.05.2021 | Boundless Bio Raises $105 Million Series B Financing | Boundless Bio ... Take 1 minute to subscribe and you'll get this story immediately, plus: Already a ... | sdbj.com/n... |
28.04.2021 | Boundless Bio has raised a $105M Series B to advance multipl... | - | connect.or... |
28.04.2021 | Boundless Bio Raises $105M Series B | SAN DIEGO, Boundless Bio announced the closing of an oversubscribed $105 Million Series B financin... | vcnewsdail... |
28.04.2021 | Boundless Bio : Raises Oversubscribed $105 Million Series B ... | Boundless Bio, a next-generation precision oncology company developing innovative therapeutics direc... | marketscre... |
28.04.2021 | Boundless Bio Picks Up $105M | San Diego-based Boundless Bio, a company developing therapeutics for treating cancer, has raised $10... | socaltech.... |
25.09.2019 | Pursuing ‘Untapped Biology,’ Boundless Bio Receives $46.4 Mi... | Boundless Bio Inc. emerged Sept. 19 with $46.4 million in funding and a claim to new territory: extr... | sdbj.com/n... |
25.09.2019 | Boundless Bio Raises $46.4 Million In Funding | Boundless Bio, a company interrogating and targeting extrachromosomal DNA (ecDNA) in aggressive canc... | pulse2.com... |
Show more